Cost-effectiveness Analysis in the New Era of Treatment Strategies in Metastatic Urothelial Carcinoma Based on Checkmate-901 and EV302/Keynote-A39
This report presents a cost-effectiveness analysis of emerging treatment options for metastatic urothelial carcinoma. The combination of enfortumab vedotin + pembrolizumab emerged as the most effective treatment; however, it also proved to be the costliest. From a purely socioeconomic standpoint, the combination of gemcitabine/cisplatin and nivolumab represents a cost-effective alternative at least in Germany.
Authors
- Michaela Lehmann
- Richard Weiten (ORCID: https://orcid.org/0009-0008-6562-5518)
- Christian Bach (ORCID: https://orcid.org/0000-0001-6204-2327)
- Enno Storz (ORCID: https://orcid.org/0009-0002-8250-5522)
- David Pfister
- Constantin Rieger (ORCID: https://orcid.org/0009-0000-3993-7974)
- Jörg Schlüchtermann
- Axel Heidenreich
Institutions
- University of Cologne (DE)
- University of Bayreuth (DE)
Publication Details
- Journal
- European Urology Oncology
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1016/j.euo.2024.10.003
- Citations
- 11
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.30